Oligonucleotide Synthesis Market

Report Code BT 2680
Published in Apr, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Oligonucleotide Synthesis Market Size by Product (Drugs (ASO, siRNA), Synthesized Oligo (Primer), Reagents, Equipment), Type (Custom, Predesigned), Application (Therapeutic (Neurology, Rare), Research (PCR, Sequencing), Diagnostics) - Global Forecast to 2029

Overview

The size of global oligonucleotide synthesis market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach $19.7 billion by 2029, growing at a CAGR of 17.5% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The major factors driving the growth of this market are the growing use of synthesized oligonucleotides for therapeutic and diagnostic applications, ongoing developments in technologies such as next-generation sequencing (NGS) and CRISPR, increasing investments by governments and major players in life science research and synthetic biology, and a growing focus on precision/ personalized medicines.

Attractive Opportunities in the Oligonucleotide Synthesis Market

North America

The growth of the North American oligonucleotide synthesis market is primarily due to growing pharmaceutical R&D activities and rising incidence of neurological and rare diseases.

Growth in this market is primarily driven by the increasing investments towards research and development of oligonucleotide-based drugs for various neurological and rare diseases.

High complexities associated with the development of oligonucleotide-based therapies is restraining the market growth.

Growing opportunities in emerging economies and advancements in technologies such as CRISPR and NGS is likely to offer potential growth opportunities in the oligonucleotide synthesis market.

The North American market is projected to grow at the highest CAGR during the forecast period.

Global Oligonucleotide Synthesis Market Dynamics

Driver: Increasing use of synthesized oligos in therapeutic and diagnostic applications

The potential of oligonucleotide-based drugs to treat a diverse range of neurological and rare diseases is a major factor driving the growth of this market. There has been a consistent growth in the number of regulatory approvals received for these drugs. Additionally, a strong clinical pipeline exists for these drugs. Furthermore, oligonucleotides are used for genetic testing, molecular diagnostics, microarrays, and gene therapy applications. Synthesized oligos are used for accurate and sensitive detection and quantification of nucleic acids. Modified DNA/RNA oligonucleotides, such as fluorescent probes, are used to identify specific genetic sequences, allowing the detection and diagnosis of genetic disorders and infections. These applications of oligonucleotides are significantly driving the demand for synthesized oligonucleotides as well as oligonucleotide-based drugs.

Restraint: Complexities associated with therapeutic oligonucleotides

Achieving specific control over the length of the oligonucleotide while minimizing impurities is one of the major challenges faced during oligonucleotide synthesis. Waste generated during the synthesis process is another major issue related to oligonucleotide synthesis. Large amounts of nucleotides that are not incorporated into the oligonucleotide sequences are discarded as waste harmful waste. These factors, cumulatively, are restraining the growth of the market to a certain extent.

 

Opportunity: Increasing R&D investments by key players in emerging economies

Emerging economies like China, India, Japan, Brazil, and Argentina offer substantial growth opportunities for the oligonucleotide synthesis market. This is mainly due to the increasing investments by various major companies in emerging economies of the Asia Pacific and Latin America regions. For instance, in 2023, Merck KGaA, a major biotechnology company from Germany, invested USD 76 million (EUR 70 million) to expand production capabilities for high-purity reagents and increase the annual output at its site in Nantong, China. Similarly, in the same year, Insud Pharma S.L.U, a company based in Spain, opened a Spinal Muscular Atrophy (SMA) oligonucleotide development and manufacturing unit in India. This unit will focus on the production of Nusinersen, an antisense oligo that is used in the treatment of Spinal Muscular Atrophy (SMA). These developments indicate growing opportunities for players operating the market.

Challenge: Delivery of oligonucleotide drugs to specific targets

Oligonucleotide-based drug delivery is a major problem that reduces the effectiveness of oligonucleotide therapeutics. The intravenous delivery method used for the delivery of ASO drugs is not efficient, and often, drugs do not reach the target tissue in adequate quantities. Furthermore, the negative charge of these molecules makes crossing the blood-brain barrier a challenge for the drugs. Researchers are developing positively charged cell-penetrating peptides that have the ability to attach to the ASO drug allowing better cell penetration and drug availability. Thus, novel developments in this regard are expected to reduce the effect of this challenge in the coming years.

Global Oligonucleotide Synthesis Market Ecosystem Analysis

Ecosystem Analysis The ecosystem of the oligonucleotide synthesis market comprises supply side as well as demand-side entities that significantly contribute towards market growth. The demand side entities for therapeutic application (oligonucleotide-based drugs) include Hospitals mainly, while as for the research and diagnostic applications, major end users are pharma & biotech companies and diagnostic labs.

The oligonucleotide-based drugs segment of the oligonucleotide synthesis industry accounted for the largest share in 2023.

Based on product the oligonucleotide synthesis market is divided into oligonucleotide-based drugs, synthesized oligonucleotides, reagents & consumables, and equipment. In 2023, the oligonucleotide-based drugs segment held the largest share of the market. The major factors driving the growth of this segment are the increasing number of regulatory approvals received for oligonucleotide-based drugs, specifically antisense oligonucleotides and small interference RNA for the treatment of various neurological and rare diseases, growing research on the development of oligonucleotide-based drugs against common indications such as cardiovascular diseases that affect a larger patient population. Growing awareness of alternative therapies and the potential of these drugs to treat diseases that were previously deemed untreatable are among other factors that propel the market of oligonucleotide-based drugs.

The therapeutic application segment dominated the oligonucleotide synthesis industry in 2023.

Based on application, the oligonucleotide synthesis market is segmented into therapeutic, research, and diagnostic applications. In 2023, the therapeutic application segment held the largest market share as well as registered the highest market growth in the global market owing to the increasing approval for oligonucleotide-based drugs such as ASOs and siRNAs for the treatment of various neurological and rare diseases. The focus of the industry leaders to expand the use of oligo-based therapies to common diseases such as cardiovascular disease will further propel the market of oligo based therapeutic drugs. Also, factors such as the increasing need for drugs with high specificity and efficacy including oligo-based drugs along with a growing focus on personalized/ precision medicine support market growth.

North America Region Holds the Largest Share of the Oligonucleotide Synthesis Market.

The global Oligonucleotide synthesis market is segmented into six major regions—North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. North America was the largest segment in 2023 in the market, followed by Europe and the Asia Pacific. North America, comprising the US and Canada, is the largest regional segment in the market. This regional segment is projected to grow at the highest CAGR in the forecast period. The increasing R&D investments in the field of life sciences and healthcare and the growing focus on developing personalized therapeutics for various diseases are major factors supporting the large share of this market. The presence of a large number of global players in this region such as Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Maravai Lifesciences Holdings, Inc. (US), Azenta, Inc. (US), Twist Bioscience Corporation (US) among others, is another key factor contributing to the large share of this market segment.

Recent Developments of Oligonucleotide Synthesis Market industry

  • In November 2023, LCG Biosearch Technologies, a business unit of LGC Limited, acquired PolyDesign to enhance its oligonucleotide synthesis capabilities using PolyDesign's frit technology.
  • In October 2023, Integrated DNA Technologies (IDT), a subsidiary of Danaher Corporation, opened its therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This facility will produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligos.

Key Market Players

KEY PLAYERS IN THE Oligonucleotide Synthesis Market INCLUDE

  • Danaher Corporation (US)
  • Thermo Fisher Scientific Inc. (US)
  • Merck KGaA (Germany)
  • Eurofins Scientific (Luxembourg)
  • LGC Limited (UK)
  •  Agilent Technologies, Inc. (US)
  •  Kaneka Corporation (Japan)
  •  Maravai Lifesciences Holdings, Inc. (US)
  •  Azenta, Inc. (US)
  •  Twist Bioscience Corporation (US)
  • Genscript Biotech Corporation (US)
  • Biogen Inc. (US)
  •  Alnylam Pharmaceuticals, Inc. (US)
  •  Sarepta Therapeutics, Inc. (US)
  •  Astrazeneca (UK)
  •  Astellas Pharma Inc. (Japan)
  •  Jazz Pharmaceuticals Plc (Ireland)
  •  Nippon Shinyaku, Co. Ltd. (Japan)
  •  Ionis Pharmaceuticals, Inc. (US)
  • Novartis AG (Switzerland).

Want to explore hidden markets that can drive new revenue in Oligonucleotide Synthesis Market?

Scope of the Report

Report Attribute Details
Market Revenue Size in 2024 $8.8 billion
Projected Revenue Size by 2029 $19.7 billion
Industry Growth Rate Poised to Grow at a CAGR of 17.5%
Market Driver Increasing use of synthesized oligos in therapeutic and diagnostic applications
Market Opportunity Increasing R&D investments by key players in emerging economies

 

Key Questions Addressed by the Report

What is the projected market revenue value of the global oligonucleotide synthesis market?
The global oligonucleotide synthesis market boasts a total revenue value of $19.7 billion by 2029.
What is the estimated growth rate (CAGR) of the global oligonucleotide synthesis market?
The global oligonucleotide synthesis market has an estimated compound annual growth rate (CAGR) of 17.5% and a revenue size in the region of $8.8 billion in 2024.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Synthesis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
40
RESEARCH METHODOLOGY
46
EXECUTIVE SUMMARY
60
PREMIUM INSIGHTS
63
MARKET OVERVIEW
66
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing use of synthesized oligos in therapeutic and diagnostic applications
    - Technological advancements
    - Growing government investments in life science research and synthetic biology
    - Growing focus on precision/personalized medicine
    RESTRAINTS
    - Complexities associated with therapeutic oligonucleotides
    OPPORTUNITIES
    - Increasing R&D investments by key players in emerging economies
    CHALLENGES
    - Lack of standard regulations
    - Delivery of oligonucleotide drugs to specific targets
  • 5.3 MARKET TRENDS
    FOCUS ON DEVELOPING NEW DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS
    FOCUS ON DEVELOPING NEW TECHNOLOGIES FOR SUSTAINABLE AND LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES
    FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION
    GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL AND RARE DISEASES
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    ROLE IN ECOSYSTEM
  • 5.8 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Solid-phase synthesis
    - Liquid-phase synthesis
    - Enzymatic oligo synthesis
    COMPLEMENTARY TECHNOLOGIES
    - Polymerase chain reaction (PCR)
    - Next-generation sequencing
    ADJACENT TECHNOLOGIES
    - Clustered regularly interspaced short palindromic repeats (CRISPR)
  • 5.9 PRICING ANALYSIS
  • 5.10 PATENT ANALYSIS
    PATENTS FILED, BY DOCUMENT TYPE, 2012–2023
  • 5.11 PIPELINE ANALYSIS
  • 5.12 TRADE ANALYSIS
  • 5.13 KEY CONFERENCES & EVENTS IN 2024–2025
  • 5.14 REGULATORY LANDSCAPE
    REGULATORY ANALYSIS
    REGULATORY BODIES
  • 5.15 PORTER’S FIVE FORCES ANALYSIS
    DEGREE OF COMPETITION
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
  • 5.16 KEY STAKEHOLDERS & BUYING CRITERIA
    INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: HOSPITALS
  • 5.17 KEY BUYING CRITERIA
    BUYING CRITERIA OF END USERS FOR SYNTHESIZED OLIGONUCLEOTIDE PRODUCTS
    BUYING CRITERIA FOR SYNTHESIZED OLIGONUCLEOTIDES, BY END USER
    BUYING CRITERIA OF HOSPITALS FOR OLIGONUCLEOTIDE THERAPEUTIC PRODUCTS
    BUYING CRITERIA FOR OLIGONUCLEOTIDE-BASED THERAPEUTIC PRODUCTS BY HOSPITALS
  • 5.18 CASE STUDY ANALYSIS
    CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT
    CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING
    CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA
  • 5.19 INVESTMENT/FUNDING SCENARIO
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT
106
  • 6.1 INTRODUCTION
  • 6.2 OLIGONUCLEOTIDE-BASED DRUGS
    OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
    - Antisense oligonucleotide-based drugs
    - siRNA oligonucleotide-based drugs
    - Other oligonucleotide-based drugs
  • 6.3 SYNTHESIZED OLIGONUCLEOTIDES
    SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
    - Primers
    - Probes
    - DNA oligonucleotides
    - RNA oligonucleotides
    - Other synthesized oligonucleotides
    SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
    - Custom oligonucleotides
    - Predesigned oligonucleotides
  • 6.4 REAGENTS & CONSUMABLES
    GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS
  • 6.5 EQUIPMENT
    TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION
155
  • 7.1 INTRODUCTION
  • 7.2 THERAPEUTIC APPLICATIONS
    THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
    - Neurological disorders
    - Rare diseases
    - Other diseases
  • 7.3 RESEARCH APPLICATIONS
    PCR
    - Increasing use of PCR in molecular biology research to drive market growth
    SEQUENCING
    - Advancements in sequencing technologies and low cost of DNA sequencing to boost growth
    OTHER RESEARCH APPLICATIONS
  • 7.4 DIAGNOSTIC APPLICATIONS
    INCREASING DEMAND FOR RELIABLE, SPECIFIC, AND FAST METHODS FOR DETECTION OF VARIOUS DISEASES TO SUPPORT GROWTH
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER
186
  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS
    INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET GROWTH
  • 8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO DRIVE GROWTH
  • 8.4 DIAGNOSTIC LABORATORIES
    GROWING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL GROWTH
  • 8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
    WIDE RANGE OF CUSTOMIZED OLIGO SERVICES PROVIDED BY CROS & CMOS TO FAVOR MARKET GROWTH
  • 8.6 ACADEMIC RESEARCH INSTITUTES
    GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET GROWTH
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION
205
  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    US
    - Government initiatives and strategic developments by major players to drive market growth
    CANADA
    - Strong research infrastructure and availability of funding to support market growth
    NORTH AMERICA: RECESSION IMPACT
  • 9.3 EUROPE
    GERMANY
    - Government and private funding towards health research to support market growth
    UK
    - Strategic collaborations and partnerships between key market players to favor market growth
    FRANCE
    - Government initiatives to strengthen R&D activities and growing awareness to propel market growth
    ITALY
    - Increasing research spending and presence of major pharmaceutical and biotechnology companies to drive market
    SPAIN
    - Research and expansion initiatives to propel market growth
    REST OF EUROPE
    EUROPE: RECESSION IMPACT
  • 9.4 ASIA PACIFIC
    CHINA
    - Expansion of major biotechnology and pharmaceutical companies in China to boost market
    JAPAN
    - Growing research initiatives and strategic developments to drive market growth in Japan
    INDIA
    - Strong initiatives to develop bioclusters and increasing adoption of genomic technologies to aid market growth
    AUSTRALIA
    - Increasing government initiatives and research funding to support market growth
    SOUTH KOREA
    - Growing research activities and strategic expansions in field of oligonucleotide synthesis to propel market growth
    REST OF ASIA PACIFIC
    ASIA PACIFIC: RECESSION IMPACT
  • 9.5 LATIN AMERICA
    BRAZIL
    - Availability of major oligo-based therapies to support market growth
    MEXICO
    - Growing adoption of NGS technology and increasing research and awareness towards oligonucleotide-based therapies to support growth
    ARGENTINA
    - Increase in research collaborations and government support to boost market growth
    REST OF LATIN AMERICA
    LATIN AMERICA: RECESSION IMPACT
  • 9.6 MIDDLE EAST
    GCC COUNTRIES
    - Saudi Arabia (KSA)
    - United Arab Emirates (UAE)
    - Rest of GCC Countries
    REST OF MIDDLE EAST
    MIDDLE EAST: RECESSION IMPACT
  • 9.7 AFRICA
    GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH
    AFRICA: RECESSION IMPACT
COMPETITIVE LANDSCAPE
311
  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    KEY PLAYERS STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2021–2024
    KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS), 2021–2024
  • 10.3 REVENUE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
  • 10.4 MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
  • 10.5 REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS)
  • 10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
  • 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT ANALYSIS
  • 10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 10.9 COMPETITIVE SCENARIO
    PRODUCT APPROVALS
  • 10.10 VALUATION AND FINANCIAL METRICS OF OLIGONUCLEOTIDE SYNTHESIS MARKET VENDORS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
  • 10.11 VALUATION AND FINANCIAL METRICS OF OLIGONUCLEOTIDE SYNTHESIS MARKET VENDORS (THERAPEUTIC APPLICATIONS)
  • 10.12 BRAND/PRODUCT COMPARATIVE ANALYSIS
    BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH AND DIAGNOSTIC APPLICATIONS)
    BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS)
COMPANY PROFILES
340
  • 11.1 KEY PLAYERS
    DANAHER CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    MERCK KGAA
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    LGC LIMITED
    - Business overview
    - Products offered
    - Recent developments
    EUROFINS SCIENTIFIC
    - Business overview
    - Products offered
    - Recent developments
    AGILENT TECHNOLOGIES, INC.
    - Business overview
    - Products offered
    - Recent developments
    KANEKA CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    MARAVAI LIFESCIENCES HOLDINGS, INC.
    - Business overview
    - Products offered
    - Recent developments
    AZENTA, INC.
    - Business overview
    - Products offered
    TWIST BIOSCIENCE CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    GENSCRIPT BIOTECH CORPORATION
    - Business overview
    - Products offered
    - Recent developments
  • 11.2 KEY PLAYERS (THERAPEUTIC PRODUCTS)
    BIOGEN INC.
    - Business overview
    - Products offered
    - Recent developments
    ALNYLAM PHARMACEUTICALS, INC.
    - Business overview
    - Products offered
    - Recent developments
    SAREPTA THERAPEUTICS, INC.
    - Business overview
    - Products offered
    - Recent developments
    ASTRAZENECA
    - Business overview
    - Products offered
    - Recent developments
    ASTELLAS PHARMA INC.
    - Business overview
    - Products offered
    - Recent developments
    JAZZ PHARMACEUTICALS PLC
    - Business overview
    - Products offered
    NIPPON SHINYAKU, CO. LTD. (NS PHARMA, INC.)
    - Business overview
    - Products offered
    IONIS PHARMACEUTICALS, INC.
    - Business overview
    - Products offered
    - Recent developments
    NOVARTIS AG
    - Business overview
    - Products offered
    - Recent developments
  • 11.3 OTHER PLAYERS
    OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
    BIOLEGIO BV
    BIOLYTIC LAB PERFORMANCE, INC.
    BIOCOMMA LIMITED
    REVVITY, INC. (THROUGH SUBSIDIARY HORIZON DISCOVERY LTD.)
    BIO-SYNTHESIS, INC.
    CREATIVE BIOGENE
    REPROCELL, INC. (THROUGH SUBSIDIARY BIOSERVE)
APPENDIX
424
  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 12.3 RELATED REPORTS
  • 12.4 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
  • TABLE 2 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
  • TABLE 3 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
  • TABLE 4 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016-2023)
  • TABLE 5 LIST OF ACQUISITIONS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
  • TABLE 6 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
  • TABLE 7 INDICATIVE PRICING OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
  • TABLE 8 AVERAGE SELLING PRICE FOR MAJOR OLIGONUCLEOTIDE-BASED DRUGS
  • TABLE 9 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
  • TABLE 10 OLIGONUCLEOTIDE-BASED DRUGS IN CLINICAL PIPELINE
  • TABLE 11 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES & EVENTS
  • TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 19 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 20 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 21 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 22 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 23 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 24 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 25 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 26 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME, BY PRODUCT, 2022–2029 (NUMBER OF VIALS)
  • TABLE 27 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 28 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
  • TABLE 29 ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 30 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 EUROPE: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 32 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 33 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 34 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 35 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS
  • TABLE 37 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 38 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 39 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 41 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 42 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 43 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 APPROVED OTHER OLIGONUCLEOTIDE-BASED DRUGS
  • TABLE 45 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 46 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 48 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 49 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 50 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 53 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 54 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 58 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 59 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 60 OLIGONUCLEOTIDE PRIMERS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 61 NORTH AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 EUROPE: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 64 LATIN AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 65 MIDDLE EAST: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 66 GCC COUNTRIES: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 OLIGONUCLEOTIDE PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 68 NORTH AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 69 EUROPE: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 70 ASIA PACIFIC: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 71 LATIN AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 72 MIDDLE EAST: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 73 GCC COUNTRIES: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 74 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 75 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 78 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 79 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 80 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 81 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 82 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 83 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 85 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 86 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 87 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 88 OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 90 EUROPE: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 92 LATIN AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 93 MIDDLE EAST: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 94 GCC COUNTRIES: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 95 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 96 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 97 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 98 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 99 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 100 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 101 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 102 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 103 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 104 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 105 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 106 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 107 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 108 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 109 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 110 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 111 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 112 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 114 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 115 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 116 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 117 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 118 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 119 EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 121 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 122 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 123 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 124 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 125 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 126 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 127 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 129 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 130 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 131 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 132 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 133 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 134 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 135 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 136 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 137 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 138 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 139 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 140 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 141 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 142 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 143 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 144 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 145 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 146 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 152 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 153 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 154 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 155 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 156 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 157 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 158 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 159 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 160 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 161 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 167 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 168 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 169 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 170 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 171 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 173 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 174 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 175 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 176 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 178 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 180 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 181 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 182 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 183 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 184 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 185 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 186 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 187 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 188 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 189 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 190 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 191 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 192 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 193 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 194 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 195 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 196 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 197 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 198 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 199 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 201 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 202 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 203 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 204 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 205 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 206 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 207 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 208 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 210 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 211 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 212 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 213 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 214 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 216 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 217 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 218 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 219 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 220 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 221 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 222 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 223 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 224 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 225 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 226 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 227 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 228 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 229 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 230 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 231 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 232 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 233 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 234 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 235 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 236 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 237 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 238 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 239 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 240 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 241 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 242 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 243 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 244 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 245 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 246 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 247 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 248 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 249 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 250 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 251 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 252 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 253 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 254 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 255 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 256 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 257 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 258 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 259 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 261 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 262 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 263 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 264 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 265 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 266 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 267 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 268 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 269 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 270 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 271 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 272 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 273 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 274 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 275 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 276 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 277 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 278 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 279 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 280 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 281 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 282 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 283 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 284 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 285 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 286 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 287 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 288 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 289 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 290 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 291 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 292 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 293 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 294 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 295 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 296 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 297 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 298 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 299 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 300 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 301 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 302 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 303 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 304 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 305 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 306 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 307 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 308 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 309 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 310 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 311 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 312 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 313 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 314 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 315 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 316 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 317 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 318 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 319 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 320 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 321 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 322 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 323 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 324 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 325 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 326 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 327 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 328 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 329 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 330 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 331 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 332 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 333 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 334 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 335 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 336 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 337 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 338 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 339 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 340 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 341 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 342 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 343 AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 344 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 345 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 346 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 347 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 348 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 349 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 350 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 351 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 352 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 353 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 354 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 355 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 356 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 357 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 358 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 359 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 360 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 361 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 362 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 363 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 364 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 365 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 366 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 367 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 368 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 369 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 370 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 371 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 372 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 373 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 374 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 375 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 376 BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 377 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 378 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 379 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 380 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 381 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 382 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 383 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 384 MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 385 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 386 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 387 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 388 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 389 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 390 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 391 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 392 ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 393 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 394 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 395 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 396 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 397 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 398 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 399 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 400 REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 401 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 402 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 403 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 404 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 405 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 406 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 407 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 408 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 409 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 410 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 411 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 412 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 413 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 414 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 415 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 416 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 417 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 418 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 419 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 420 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 421 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 422 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 423 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 424 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 425 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 426 SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 427 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 428 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 429 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 430 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 431 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 432 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 433 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 434 UAE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 435 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 436 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 437 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 438 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 439 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 440 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 441 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 442 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 443 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 444 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 445 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 446 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 447 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 448 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 449 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 450 REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 451 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 452 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 453 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 454 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 455 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 456 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 457 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 458 AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 459 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 460 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 461 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 462 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
  • TABLE 463 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 464 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 465 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): DEGREE OF COMPETITION
  • TABLE 466 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): DEGREE OF COMPETITION
  • TABLE 467 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): PRODUCT FOOTPRINT
  • TABLE 468 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): APPLICATION FOOTPRINT
  • TABLE 469 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): REGIONAL FOOTPRINT
  • TABLE 470 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): REGIONAL FOOTPRINT
  • TABLE 471 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): PRODUCT FOOTPRINT
  • TABLE 472 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): APPLICATION FOOTPRINT
  • TABLE 473 DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 474 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 475 OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT APPROVALS, JANUARY 2021–FEBRUARY 2024
  • TABLE 476 OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS, JANUARY 2021-FEBRUARY 2024
  • TABLE 477 OLIGONUCLEOTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2021- FEBRUARY 2024
  • TABLE 478 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 479 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 480 DANAHER CORPORATION: DEALS
  • TABLE 481 DANAHER CORPORATION: EXPANSIONS
  • TABLE 482 DANAHER CORPORATION: OTHER DEVELOPMENTS
  • TABLE 483 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 484 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 485 THERMO FISHER SCIENTIFIC INC.: DEALS
  • TABLE 486 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 487 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 488 MERCK KGAA: EXPANSIONS
  • TABLE 489 LGC LIMITED: COMPANY OVERVIEW
  • TABLE 490 LGC LIMITED: PRODUCTS OFFERED
  • TABLE 491 LGC LIMITED: DEALS
  • TABLE 492 LGC LIMITED: EXPANSIONS
  • TABLE 493 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 494 EUROFINS SCIENTIFIC: PRODUCTS OFFERED
  • TABLE 495 EUROFINS SCIENTIFIC: DEALS
  • TABLE 496 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 497 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • TABLE 498 AGILENT TECHNOLOGIES, INC.: EXPANSIONS
  • TABLE 499 KANEKA CORPORATION: COMPANY OVERVIEW
  • TABLE 500 KANEKA CORPORATION: PRODUCTS OFFERED
  • TABLE 501 KANEKA CORPORATION: EXPANSIONS
  • TABLE 502 MARAVAI LIFESCIENCES HOLDINGS, INC.: COMPANY OVERVIEW
  • TABLE 503 MARAVAI LIFESCIENCES HOLDINGS, INC.: PRODUCTS OFFERED
  • TABLE 504 MARAVAI LIFESCIENCES HOLDINGS, INC.: DEALS
  • TABLE 505 AZENTA, INC.: COMPANY OVERVIEW
  • TABLE 506 AZENTA, INC.: PRODUCTS OFFERED
  • TABLE 507 TWIST BIOSCIENCE CORPORATION: COMPANY OVERVIEW
  • TABLE 508 TWIST BIOSCIENCE CORPORATION: PRODUCTS OFFERED
  • TABLE 509 TWIST BIOSCIENCE CORPORATION: DEALS
  • TABLE 510 GENSCRIPT BIOTECH CORPORATION: COMPANY OVERVIEW
  • TABLE 511 GENSCRIPT BIOTECH CORPORATION: PRODUCTS OFFERED
  • TABLE 512 GENSCRIPT BIOTECH CORPORATION: EXPANSIONS
  • TABLE 513 BIOGEN INC.: COMPANY OVERVIEW
  • TABLE 514 BIOGEN INC.: PRODUCTS OFFERED
  • TABLE 515 BIOGEN INC.: PRODUCT APPROVALS
  • TABLE 516 BIOGEN INC.: DEALS
  • TABLE 517 BIOGEN INC.: EXPANSIONS
  • TABLE 518 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 519 ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED
  • TABLE 520 ALNYLAM PHARMACEUTICALS INC.: PRODUCT APPROVALS
  • TABLE 521 ALNYLAM PHARMACEUTICALS INC.: DEALS
  • TABLE 522 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 523 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED
  • TABLE 524 SAREPTA THERAPEUTICS: PRODUCT APPROVALS
  • TABLE 525 SAREPTA THERAPEUTICS: DEALS
  • TABLE 526 SAREPTA THERAPEUTICS: EXPANSIONS
  • TABLE 527 ASTRAZENECA: COMPANY OVERVIEW
  • TABLE 528 ASTRAZENECA: PRODUCTS OFFERED
  • TABLE 529 ASTRAZENECA: DEALS
  • TABLE 530 ASTRAZENECA: PRODUCT APPROVALS
  • TABLE 531 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
  • TABLE 532 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
  • TABLE 533 ASTELLAS PHARMA INC.: DEALS
  • TABLE 534 ASTELLAS PHARMA INC.: PRODUCT APPROVALS
  • TABLE 535 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW
  • TABLE 536 JAZZ PHARMACEUTICALS PLC: PRODUCTS OFFERED
  • TABLE 537 NIPPON SHINYAKU, CO. LTD.: COMPANY OVERVIEW
  • TABLE 538 NIPPON SHINYAKU, CO. LTD.: PRODUCTS OFFERED
  • TABLE 539 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 540 IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED
  • TABLE 541 IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS
  • TABLE 542 IONIS PHARMACEUTICALS, INC.: DEALS
  • TABLE 543 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 544 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 545 NOVARTIS AG: PRODUCT APPROVALS
  • TABLE 546 NOVARTIS AG: DEALS
LIST OF FIGURES
 
  • FIGURE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION
  • FIGURE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: REGIONAL SEGMENTATION
  • FIGURE 3 RESEARCH DESIGN
  • FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
  • FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1A (REVENUE SHARE ANALYSIS FOR RESEARCH & DIAGNOSTIC APPLICATIONS), 2023
  • FIGURE 7 MARKET SIZE ESTIMATION: APPROACH 1B (REVENUE SHARE ANALYSIS FOR THERAPEUTIC APPLICATIONS), 2023
  • FIGURE 8 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION (RESEARCH AND DIAGNOSTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2023
  • FIGURE 9 ILLUSTRATIVE EXAMPLE OF BIOGEN INC. (THERAPEUTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2023
  • FIGURE 10 MARKET VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 11 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 12 CAGR PROJECTIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET, 2024–2029
  • FIGURE 13 CAGR PROJECTIONS: OLIGONUCLEOTIDE-BASED DRUGS MARKET (THERAPEUTIC APPLICATIONS), 2024–2029
  • FIGURE 14 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN OLIGONUCLEOTIDE SYNTHESIS MARKET
  • FIGURE 15 DATA TRIANGULATION METHODOLOGY
  • FIGURE 16 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2024−2029 (USD MILLION)
  • FIGURE 19 GEOGRAPHICAL SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET
  • FIGURE 20 INCREASING USE OF SYNTHESIZED OLIGOS TO DRIVE MARKET GROWTH
  • FIGURE 21 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
  • FIGURE 22 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2029
  • FIGURE 23 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 24 NORTH AMERICA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 25 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR OLIGONUCLEOTIDE MANUFACTURERS
  • FIGURE 27 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
  • FIGURE 28 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
  • FIGURE 29 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET
  • FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2012–DECEMBER 2023)
  • FIGURE 31 NUMBER OF ONGOING CLINICAL TRIALS FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COMPANY
  • FIGURE 32 NUMBER OF ESTIMATED LAUNCHES, 2024–2028
  • FIGURE 33 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIGURE 34 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIGURE 35 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2021–2023
  • FIGURE 36 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS), BY KEY PLAYER, 2023
  • FIGURE 37 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2021–2023
  • FIGURE 38 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS), BY KEY PLAYER, 2023
  • FIGURE 39 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2023
  • FIGURE 40 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2023
  • FIGURE 41 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): COMPANY FOOTPRINT
  • FIGURE 42 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): COMPANY FOOTPRINT
  • FIGURE 43 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2023
  • FIGURE 44 EV/EBITDA OF KEY VENDORS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
  • FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
  • FIGURE 46 EV/EBITDA OF KEY VENDORS (THERAPEUTIC APPLICATIONS)
  • FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (THERAPEUTIC APPLICATIONS)
  • FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 49 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 50 MERCK KGAA: COMPANY SNAPSHOT (2023)
  • FIGURE 51 LGC LIMITED: COMPANY SNAPSHOT (2023)
  • FIGURE 52 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023)
  • FIGURE 53 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 54 KANEKA CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 55 MARAVAI LIFESCIENCES HOLDINGS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 56 AZENTA, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 57 TWIST BIOSCIENCE CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 58 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 59 BIOGEN INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 60 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 61 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2023)
  • FIGURE 62 ASTRAZENECA: COMPANY SNAPSHOT (2023)
  • FIGURE 63 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 64 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 65 NIPPON SHINYAKU, CO. LTD.: COMPANY SNAPSHOT (2022)
  • FIGURE 66 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 67 NOVARTIS AG: COMPANY SNAPSHOT (2023)

This study involved four major activities in estimating the current size of the oligonucleotide synthesis market. Exhaustive secondary research was conducted to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.  

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), Food and Drug Administration (FDA), National Center for Biotechnology Information (NCBI), Industry Association of Synthetic Biology (IASB), Biotechnology Innovation Organization (BIO), and Genome Canada. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information and assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Oligonucleotide Synthesis Market Size, and Share

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue. As of 2021, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the oligonucleotide synthesis market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the oligonucleotide synthesis business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Oligonucleotide Synthesis Market Size: Sum of Research & Diagnostic Applications market and  Therapeutic applications Market for oligonucleotide synthesis (A+B)

A: Research & Diagnostic Applications market for oligonucleotide synthesis

Oligonucleotide Synthesis Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

B: Therapeutic applications Market for oligonucleotide synthesis

Oligonucleotide Synthesis Market Size, and Share

Top-down Approach-

Oligonucleotide Synthesis Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Oligonucleotide synthesis refers to the chemical process of creating nucleic acid fragments with specific chemical structures or sequences of varying sizes to form a desired end product. These fragments, known as oligonucleotides, have a wide range of applications in medical and life science research. They can be used for DNA sequencing and amplification, detecting complementary DNA or RNA through hybridization, creating artificial genes, and introducing targeted genetic mutations.

Oligonucleotides are also used to develop therapeutic drugs. These drugs are produced chemically and have different mechanisms of action, such as interfering with gene expressions, blocking the production of harmful proteins, or restoring the function of mutated genes.

Key Stakeholders

  • Pharmaceutical & biotechnology companies
  • Hospitals
  • Diagnostic laboratories
  • Academic researchers and government research organizations
  • Private research institutes
  • Custom oligonucleotide service providers
  • Contract manufacturing organizations (CMOs)
  • Oligonucleotide equipment manufacturers
  • Contract research organizations (CROs)
  • Market research and consulting firms
  • Venture capitalists

Report Objectives

  • To define, describe, and forecast the global oligonucleotide synthesis market based on the product, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oligonucleotide synthesis market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the oligonucleotide synthesis market.
  • To analyze and provide investment and funding activities, brand/product comparative analysis, and; vendor valuation and financial metrics of the oligonucleotide synthesis market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles

Previous Versions of this Report

Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligo (Primer), Reagents), Type (Custom, Predesigned), Application (Therapeutic (ASO, siRNA), Research ((PCR, Sequencing, Diagnostics)), End User (Pharma, CROS, CMOs) - Global Forecast to 2027

Report Code BT 2680
Published in Nov, 2022, By MarketsandMarkets™

Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic), End User (Hospital, Pharma, CROs) - Global Forecast to 2026

Report Code BT 2680
Published in Apr, 2021, By MarketsandMarkets™

Oligonucleotide Synthesis Market by Product (Probe, Linkers, Adaptor, Drugs, Reagent, Equipment), Type (Custom, Pre design), Application (PCR, DNA, RNAi, Research, Therapeutic), End User (Hospital, Pharmaceutical, Biotechnology) - Global Forecast to 2024

Report Code BT 2680
Published in Apr, 2019, By MarketsandMarkets™

Oligonucleotide Synthesis Market by Product (Primer, Probe, Linker, Adaptor, Custom, Reagent, Equipment), Application (PCR, DNA, RNAi, Research, Therapeutic), End User (Academic, Pharmaceutical, Biotechnology) - Global Forecast to 2022

Report Code BT 2680
Published in Feb, 2018, By MarketsandMarkets™

Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, Custom, Predesigned, Reagent Equipment), Application (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, Biotechnology) - Forecasts to 2021

Report Code BT 2680
Published in Dec, 2016, By MarketsandMarkets™

Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, Custom Oligos, Reagent, Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global Forecast to 2020

Report Code BT 2680
Published in Nov, 2015, By MarketsandMarkets™

Oligonucleotide Synthesis Market by Product & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical & Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global Forecast to 2019

Report Code BT 2680
Published in Aug, 2014, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Oligonucleotide Synthesis Market

DMCA.com Protection Status